Clinical trial
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With…
NCT00077116 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00077116 |
|---|---|
| Title | Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome |
| Official title | Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin, idarubicin, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy |
| Enrollment | 31 |
| Start date | Nov 1, 2003 |
| Primary completion | Nov 1, 2006 |
| First posted | Feb 11, 2004 |
| Last update posted | Jul 16, 2012 |
| Countries | Belgium, Germany, Netherlands, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: